Status:
COMPLETED
Triple Therapy in Septic Shock Patients
Lead Sponsor:
Air Force Specialized Hospital, Cairo, Egypt
Conditions:
Septic Shock
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
this study is conducted to evaluate the role of the novel triple therapy combination in reducing the mortality rate, reducing the shock time, and reversal of organ damage. the study includes two arms...
Detailed Description
Background: "Sepsis" is a life-threatening organ dysfunction caused by the dysregulated host response to infection. Septic Shock: Subset of sepsis with circulatory and cellular/metabolic dysfunction ...
Eligibility Criteria
Inclusion
- Age \>18 years.
- Diagnosis of septic shock has been established (need vasopressors to maintain MAP ≥ 65, lactate ≥ 2mmol/L and SOFA score ≥2) \[25,26\].
Exclusion
- Pregnancy and lactation.
- Refusal of attending staff or patient family.
- Contraindication to any of the components of the triple therapy regimen such as (hypersensitivity to vitamin C and Patients with G6PD deficiency).
- Patients on immunosuppressive medications and oncology patients. Do not resuscitate/do not intubate (DNR, DNI) patients
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2020
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04508946
Start Date
August 1 2019
End Date
November 9 2020
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Air Force Specialized Hospital
Cairo, Egypt, 4260010